Sort   by:  
 Page size 
UnknownCheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Not available
S-EPMC6161834 | biostudies-literature
UnknownFrequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Not available
S-EPMC7065327 | biostudies-literature
UnknownNew paradigm for stage III melanoma: from surgery to adjuvant treatment.
Not available
S-EPMC6693227 | biostudies-literature
UnknownSoluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Not available
S-EPMC11028053 | biostudies-literature
UnknownRetrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Not available
S-EPMC8613139 | biostudies-literature
UnknownOutcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Not available
S-EPMC10702308 | biostudies-literature
UnknownCharacterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.
Not available
S-EPMC10605297 | biostudies-literature
UnknownAn Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival.
Not available
S-EPMC7523509 | biostudies-literature
UnknownSequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Not available
S-EPMC10761671 | biostudies-literature
Sort   by:  
 Page size